SAN FRANCISCO, CA — June 18, 2002 —
New findings suggest that the oral agent metformin is safe and well tolerated in adolescents with type 1 diabetes, and may serve as a useful adjunct to conventional management in those with poor metabolic control.
The results were reported at the 62nd Scientific Sessions of the American Diabetes Association (ADA). Dr. Jill Hamilton, with The Hospital for Sick Children and the University of Toronto, Canada, and colleagues conducted a randomized, double-blind, placebo-controlled trial of standard diabetes care and metformin (25 mg/kg/d to a maximum of 2000 mg/d) or placebo taken for three months, in 27 adolescents with type 1 diabetes.
Metformin is an oral agent which improves insulin sensitivity, glycemic control, and reduces insulin requirements in type 2 diabetes. Insulin-sensitizing agents may be ideal adjunctive agents for the adolescent type 1 diabetic in poor metabolic control, with high insulin requirements and insulin resistance related to puberty.
“During adolescence, metabolic control in type 1 diabetes typically worsens,” she said. This may be due in part to the physiologic effects of puberty, which result in decreased insulin sensitivity.” Results showed that short-term metformin therapy improves hemoglobin A1c and decreases the insulin dose with no weight gain in type 1 diabetic teens and clinical evidence of insulin resistance.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!